The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...

After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its fourth quarter and full-year 2024 financial results, along with ...

Eli Lilly and Company will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, ...

Tori Lyon, CEO of Jericho Project, the nationally-acclaimed nonprofit ending homelessness in New York, rang the closing bell of the New York Stock Exchange on February 21, 2025, in celebration of the ...